NIKA Stock Overview
Engages in the development and distribution of various pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Nika Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.31 |
| 52 Week High | US$13.99 |
| 52 Week Low | US$0.03 |
| Beta | 0 |
| 11 Month Change | -47.37% |
| 3 Month Change | -47.90% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| NIKA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.6% | 0.7% |
| 1Y | n/a | 20.9% | 32.3% |
Return vs Industry: Insufficient data to determine how NIKA performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how NIKA performed against the US Market.
Price Volatility
| NIKA volatility | |
|---|---|
| NIKA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NIKA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NIKA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Dimitar Savov | www.nikapharmaceuticals.com |
Nika Pharmaceuticals, Inc. engages in the development and distribution of various pharmaceutical products. It develops dietary supplements and antiviral drugs; and thymus nuclear glycoprotein (TNG) for the treatment of HIV. The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika Pharmaceuticals, Inc. in May 2022.
Nika Pharmaceuticals, Inc. Fundamentals Summary
| NIKA fundamental statistics | |
|---|---|
| Market cap | US$317.87m |
| Earnings (TTM) | -US$131.48k |
| Revenue (TTM) | US$156.00 |
Over9,999x
P/S Ratio-2,418x
P/E RatioIs NIKA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NIKA income statement (TTM) | |
|---|---|
| Revenue | US$156.00 |
| Cost of Revenue | US$0 |
| Gross Profit | US$156.00 |
| Other Expenses | US$131.64k |
| Earnings | -US$131.48k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00013 |
| Gross Margin | 100.00% |
| Net Profit Margin | -84,283.33% |
| Debt/Equity Ratio | -256.4% |
How did NIKA perform over the long term?
See historical performance and comparison